DHCR7 (7-Dehydrocholesterol Reductase)

P=N/A, N=130, Not yet recruiting, The First Hospital of Jiaxing; The First Hospital of Jiaxing

In vitro functional assays demonstrated that either DHCR7 knockdown or treatment with the targeted inhibitor tamoxifen significantly suppressed AML cell proliferation...Mechanistic investigations further revealed that DHCR7 exerts pro-leukaemic effects through activation of the IL-6/JAK2/STAT3 signalling axis. Collectively, this study establishes the novel function of DHCR7 in AML pathogenesis and provides robust evidence supporting its potential as a therapeutic target for AML.

In contrast, from days three to seven post-infection, there was significant upregulation of avidin (AVD), a biotin-binding protein, and versican (VCAN), which is linked to tissue remodelling and inflammation. These findings correlate with the disease's progression from initial liver infection to widespread bacterial presence, suggesting value as host biomarkers for effective SLD monitoring and the development of targeted therapies.

DHCR7 deficiency significantly reduced tumorigenicity in vivo. DHCR7 regulates the progression of CRC both in vitro and in vivo through the PI3K/AKT/mTOR signaling axis and affects the cholesterol levels in CRC.

DHCR7, as a key gene in CMS, is closely related to immune suppression and poor prognosis. Inhibition of DHCR7 can improve the tumor immune microenvironment and enhance the efficacy of immunotherapy, suggesting that DHCR7 is a potential new target for LUAD immunotherapy.

Targeting cholesterol biosynthesis by inhibiting the terminal steps via DHCR7 showed therapeutic effects in ovarian cancer cell lines and synergized with standard-of-care carboplatin treatment. This study demonstrates the power of spatially resolved quantitative proteomics in understanding early carcinogenesis and provides a rich resource for biomarker and drug target research.

These pan-cancer analyses identify DHCR7 as a multifaceted biomarker with dual prognostic and immunotherapeutic relevance. Its involvement in tumor immune microenvironment modulation suggests potential as a therapeutic target.

Furthermore, there are similarities between the metabolic characteristics of ACC and schizophrenia, such as calcium and iron ion levels. Our multi-modal analysis comprehensively characterizes the immune microenvironment of ACC, emphasizing the synergistic regulation of metabolic and immune gene clusters that influence ACC patients' responses to immune and hormone therapies.

The integration of interpretable ML with platelet RNA data revealed robust biomarkers and context-dependent regulatory patterns relevant to early cancer detection. The proposed framework supports the potential of TEPs as a non-invasive, information-rich medium for early cancer screening.

The mechanism of DHCR7 promoting LM may be mediated by elevating cholesterol synthesis of PC cells and then activating the PI3K-Akt signaling pathway. Taken together, our findings uncover a novel molecular mechanism underlying LM in PC and highlight DHCR7 as a possible predictive biomarker or interventional target.

In vitro and in vivo experiments demonstrate that HPS@ZCJ hydrogel-mediated targeted comprehensive therapy simultaneously achieves intraoperative hemostasis, impedes primary tumor growth and prevents HCC postoperative recurrence. This study provides a promising postoperative HCC treatment strategy, leveraging TCM's therapeutic potential with significant clinical translation prospects.

These findings offer valuable insights into potential combined therapeutic strategies. We developed a robust lactylation risk prediction model for accurately forecasting BLCA prognosis and identified DHCR7 as a pivotal biomarker involved in cisplatin resistance and influencing immunotherapy efficacy in BLCA.